Newsroom

Here you will find media releases, events and contacts, as well as blog stories and product news.

The multimedia area provides photos and videos, media kits, presentations and other publications for download.

Events

Media Contacts

Media Releases

Publication of Results

Sartorius has published its business figures for 2025 on Feburary 16, 2026.

  Media Release

  Annual Report 2025 (PDF) 

  Preliminary Results

  Multimedia

Subscribe to Media Releases

Media Collection

Company Presentation Sartorius

PDF 2.4 MB

Insight | Sartorius in Profile

PDF 10.4 MB

Diversity Fact Sheet

PDF 2.0 MB
icon-download

Media Kit

The Media Kit consists of the latest Annual Report, Images and the Sartorius logo.

Download Now
icon-file-image

Images and Videos

Find a selection of our press images and videos

Explore More
icon-magnifier

Need More Media Assets?

Find a selection of various media assets in the Multimedia area

Explore More

Sartorius in Profile

Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe. 

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3 billion euros. Currently, more than 10,200 employees are working for customers around the globe.

Sartorius Blog

Science Snippets

The Science Snippets Blog is a collection of short posts written to help simplify and accelerate progress in life science research and bioprocessing.

Browse Blog Articles

Product News

How We Innovate

Explore Sartorius

icon-development-growth

Investors

Explore More
icon-globe

Sustainability

Learn More
icon-e-mail
Media Contact